Observations highlight altered drug pharmacokinetics and pharmacodynamics in patients with chronic kidney disease, suggesting a need for tailored therapeutic strategies.
Key Points
Chronic kidney disease affects over 10% of the population and complicates drug management strategies.
Uremic toxins significantly modify drug pharmacokinetics, impacting absorption and bioavailability.
Drug distribution and metabolism are altered in CKD, notably reducing cytochrome P450 enzyme expression.
These changes may increase drug accumulation and adverse effects, calling for careful monitoring in CKD patients.